

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form to:

File Information Unit, Room 2E04

2900 Crystal Drive
Arlington, VA 22202-3514

Telephone: (703) 308-2733

In re Application of

Application Number

Filed

07/943852

9-11-92

Paper No. #28.

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. _____, page, _____ line _____.

United States Patent Number 7070775, column _____, line, _____ or

WIPO Pub. No. _____, page _____, line _____.

Related Information About Access to Applications Maintained in the Image File Wrapper System (IFW) and Access to Pending Applications in General

A member of the public, acting without a power to inspect, cannot order applications maintained in the IFW system through the FIU. If the member of the public is entitled to a copy of the application file, then the file is made available through the Public Patent Application Information Retrieval system (Public PAIR) on the USPTO internet web site (www.uspto.gov). Terminals that allow access to Public PAIR are available in the Public Search Room. The member of the public may also be entitled to obtain a copy of all or part of the application file upon payment of the appropriate fee. Such copies must be purchased through the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)).

For published applications that are still pending, a member of the public may obtain a copy of:

the file contents; the pending application as originally filed; or any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of: the file contents; the pending application as originally filed; or any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of the pending application as originally filed.

Signature

Date

Typed or printed name

Registration Number, if applicable

Telephone Number

FOR PTO USE ONLY

Approved by: 02 2007

OCT 02 2007 (initials)

Unit

This collection of information is required by 37 CFR 1.11 and 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Room 2E04, 2900 Crystal Drive, Arlington, Virginia.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



US007070775B2

#18

(12) **United States Patent**
Le et al.(10) **Patent No.:** **US 7,070,775 B2**
(45) **Date of Patent:** ***Jul. 4, 2006**(54) **RECOMBINANT A2-SPECIFIC TNF α**
SPECIFIC ANTIBODIES(56) **References Cited**(75) **Inventors:** **Junming Le**, Jackson Heights, NY (US); **Jan Vilcek**, New York, NY (US); **Peter Daddona**, Menlo Park, CA (US); **John Ghrayeb**, Thorndale, PA (US); **David Knight**, Berwyn, PA (US); **Scott Siegel**, Westborough, MA (US)(73) **Assignees:** **New York University**, New York, NY (US); **Centocor, Inc.**, Malvern, PA (US)(*) **Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 773 days.

This patent is subject to a terminal disclaimer.

(21) **Appl. No.:** **10/198,845**(22) **Filed:** **Jul. 18, 2002**(65) **Prior Publication Data**

US 2003/0144484 A1 Jul. 31, 2003

Related U.S. Application Data

(60) Continuation of application No. 09/756,398, filed on Jan. 8, 2001, now Pat. No. 6,835,823, which is a division of application No. 09/133,119, filed on Aug. 12, 1998, now Pat. No. 6,277,969, which is a division of application No. 08/570,674, filed on Dec. 11, 1995, now abandoned, which is a continuation-in-part of application No. 08/324,799, filed on Oct. 18, 1994, now Pat. No. 5,698,195, which is a continuation-in-part of application No. 08/192,102, filed on Feb. 4, 1994, now Pat. No. 5,656,272, and a continuation-in-part of application No. 08/192,861, filed on Feb. 4, 1994, now Pat. No. 5,919,452, and a continuation-in-part of application No. 08/192,093, filed on Feb. 4, 1994, now Pat. No. 6,284,471, which is a continuation-in-part of application No. 08/010,406, filed on Jan. 29, 1993, now abandoned, which is a continuation-in-part of application No. 08/013,413, filed on Feb. 2, 1993, now abandoned, which is a continuation-in-part of application No. 07/943,852, filed on Sep. 11, 1992, now abandoned, which is a continuation-in-part of application No. 07/853,606, filed on Mar. 18, 1992, now abandoned, which is a continuation-in-part of application No. 07/670,827, filed on Mar. 18, 1991, now abandoned.

(51) **Int. Cl.**
A61K 39/395 (2006.01)
C07K 16/28 (2006.01)(52) **U.S. Cl.** **424/145.1; 424/130.1; 424/133.1; 424/141.1; 530/387.1; 530/387.3; 530/388.1; 530/388.23**(58) **Field of Classification Search** **464/130.1, 464/145.1; 530/387.1, 388.23**
See application file for complete search history.**U.S. PATENT DOCUMENTS**

4,603,106 A	7/1986	Cerami et al.	435/7
4,816,567 A	3/1989	Cabilly et al.	
4,822,776 A	4/1989	Cerami et al.	514/21
5,075,236 A	12/1991	Yone et al.	
5,223,395 A	6/1993	Gero	435/71
5,231,024 A	7/1993	Moeller et al.	435/240.27
5,360,716 A	11/1994	Ohmoto et al.	
5,436,154 A	7/1995	Barbanti et al.	435/240.27
5,654,407 A	8/1997	Boyle et al.	530/388.15
5,658,570 A	8/1997	Newman et al.	424/184.1
5,700,788 A	12/1997	Mongelli et al.	514/91
5,730,975 A	3/1998	Hotamisligil et al.	424/130.1
5,741,488 A	4/1998	Feldman et al.	424/154.1
5,750,105 A	5/1998	Newman et al.	424/133.1
5,776,947 A	7/1998	Kroemer et al.	514/312
5,919,452 A *	7/1999	Le et al.	424/133.1
5,959,087 A	9/1999	Rathjen et al.	
6,015,558 A	1/2000	Hotamisligil et al.	424/142.1
6,172,202 B1	1/2001	Marcucci et al.	530/406
6,194,451 B1	2/2001	Alpegiani et al.	514/459
6,284,471 B1 *	9/2001	Le et al.	435/7.1
6,309,640 B1	10/2001	Cerami et al.	
6,419,927 B1	7/2002	Cerami et al.	
6,790,444 B1 *	9/2004	Le et al.	424/133.1

FOREIGN PATENT DOCUMENTS

EP	0 212 489 A2	3/1987
EP	0 218 838 A2	4/1987
EP	0 260 610 A2	3/1988
EP	0 288 088 A2	10/1988

(Continued)

OTHER PUBLICATIONSBeutler, B. et al., "Identity of tumour necrosis factor and the macrophage-secreted factor cachectin," *Nature*, 316:552-554 (1985).

(Continued)

Primary Examiner—Phillip Gambel(74) *Attorney, Agent, or Firm*—Hamilton, Brook, Smith & Reynolds, P.C.(57) **ABSTRACT**Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor- α (TNF α) and are useful in vivo diagnosis and therapy of a number of TNF α -mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.**22 Claims, 37 Drawing Sheets**